Life4me+-ის ერთ-ერთი მთავარი მიზანია აივ, სხვა სგგი, ჰეპატიტი C და ტუბერკულოზის ახალი შემთხვევების პრევენცია.

აპლიკაცია ეხმარება აივ დადებით პირებს ექიმებთან ანონიმური კომუნიკაციის დამყარებაში. ეს ყველაფერი დაგეხმარებათ ორგანიზება გაუკეთოთ მედიკამენტების მიღების განრიგს და დააყენოთ ფარული და პერსონალიზებული შეხსენებები.

ყველა სიახლე / თებერვალი 2026

არქივი

✕

25 თებერვალი 2026, 14:00

246

Doravirine/Islatravir for Initial HIV Therapy: A Two-Drug Strategy in a Three-Drug World

Doravirine/Islatravir for Initial HIV Therapy: A Two-Drug Strategy in a Three-Drug World

At CROI 2026, much of the discussion around antiretroviral therapy focused on long-acting agents and treatment optimization in experienced populations. Yet another important presentation turned to the starting point of care: initial therapy in people newly diagnosed with ...

25 თებერვალი 2026, 13:00

192

Simplifying the Complex: Switching to BIC/LEN in Treatment-Experienced People with HIV

Simplifying the Complex: Switching to BIC/LEN in Treatment-Experienced People with HIV

At CROI 2026, among presentations focused on prevention strategies and new antiviral approaches, one oral session addressed a different — and very practical — question in HIV care: what about people who are already virologically suppressed but remain on complex, multi-tablet ...

24 თებერვალი 2026, 15:00

296

Syphilis, Superbugs and Self-Testing: STIs in the Era of HIV Control

Syphilis, Superbugs and Self-Testing: STIs in the Era of HIV Control

At CROI 2026, alongside discussions of metabolic therapies and inflammation, another plenary session brought the audience back to a more familiar reality. In her lecture, “Syphilis and Superbugs: Sexually Transmitted Infections in the Era of HIV Control,” Dr. Jeanne Marrazzo ...

24 თებერვალი 2026, 14:00

386

GLP-1 Receptor Agonists at CROI 2026: Revolution, Hype — or the Beginning of a New Era?

GLP-1 Receptor Agonists at CROI 2026: Revolution, Hype — or the Beginning of a New Era?

At CROI 2026, a conference traditionally focused on antiretroviral therapy, viral persistence and immune activation, one plenary session shifted the spotlight to a different kind of molecule — yet one that may reshape far more than diabetes care.

24 თებერვალი 2026, 13:00

240

Broadly Neutralizing Antibodies and Viral Rebound: Early Signals from the RIO Trial at CROI 2026

Broadly Neutralizing Antibodies and Viral Rebound: Early Signals from the RIO Trial at CROI 2026

At the 2026 Conference on Retroviruses and Opportunistic Infections (CROI), investigators presented preliminary data from the RIO trial suggesting that exposure to broadly neutralizing antibodies (bNAbs) may alter viral rebound dynamics following treatment interruption in ...

23 თებერვალი 2026, 13:00

293

CROI 2026: Long-Acting PrEP, Limits of Resistance, and Implementation

CROI 2026: Long-Acting PrEP, Limits of Resistance, and Implementation

At the Conference on Retroviruses and Opportunistic Infections (CROI 2026) an oral abstract session was dedicated to HIV pre-exposure prophylaxis. There were no revolutionary discoveries in this session, but something more important happened: experts gave a technically mature ...

22 თებერვალი 2026, 17:00

293

CROI 2026 Conference Opens: Science, Politics, and 30 Years Searching for a Cure

CROI 2026 Conference Opens: Science, Politics, and 30 Years Searching for a Cure

The Conference on Retroviruses and Opportunistic Infections (CROI) opened on February 22, 2026, in Denver (Colorado, USA). The Life4me+ team, as always, is present at CROI and is covering the main news.